From Biology to Market Strategy: Stelios Tzellos, PhD, on Why Scientific Rigour Belongs in Oncology Intelligence
How a career that began with Epstein-Barr virus research is reshaping pharmaceutical analytics through scientific discipline, in the United Kingdom. (YorkPedia Editorial):- Barnet, Hertfordshire Jul 16, 2026 (Issuewire.com) – The pharmaceutical industry generates more oncology data each year than previous generations of researchers could have imagined. New treatments emerge from clinical trials. Pipeline assets multiply. Market models grow more sophisticated with each planning cycle. Yet in many organisations, the professionals responsible for building commercial forecasts and the scientists who understand disease mechanisms occupy separate functions and speak different languages. The result is…
Read More